LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp. LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020. Mr. Doles succeeds Dr. Joachim Franke who retired in July 2019.
David Doles joins LTS with more than 30 years’ experience in the global Fine Chemical and Life Science industry. Before joining LTS, Mr. Doles served in the Lonza Group for more than 20 years, with his most recent appointment as Vice President, Head of Materials Performance & Protection Business Unit.
“We are very pleased that David Doles will join LTS. He is a highly experienced, versatile executive with a distinguished track record. We are delighted to welcome David to strengthen and further develop our presence in the US to meet the market opportunities,” said Michael Hoffmann, Member of the LTS’ group´s management board and chairman of the LTS Corp board.
Dave Doles commented, “I am delighted to join the LTS Corp team at an exciting time. LTS Corp has an impressive track record as a leader in the American CDMO industry, particularly as a champion and pioneer of transdermal and transmucosal drug delivery. In addition to the company’s current business, LTS Corp pursues new innovative opportunities in the field of drug delivery, which offer tremendous opportunity for patient value creation.
LTS Lohmann Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representative office in Shanghai, China.
Dr. Iris Schnitzler